ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for CCXI
4.29
0.00 (0.00%)
Oct 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 4.24 - 8.25
Open     -
Vol / Avg. 0.00/72,162.00
Mkt cap 185.91M
P/E     -
Div/yield     -
EPS -0.93
Shares 43.34M
Beta     -
Inst. own 67%
Nov 5, 2014
Q3 2014 ChemoCentryx Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 5, 2014
Q2 2014 ChemoCentryx Inc Earnings Call
Aug 5, 2014
Q2 2014 ChemoCentryx Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -638.17%
Operating margin - -645.46%
EBITD margin - -635.96%
Return on average assets -35.13% -28.15%
Return on average equity -37.17% -30.25%
Employees 60 -
CDP Score - -

Address

850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company´┐Żs wholly owned subsidiary is ChemoCentryx Limited.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 51
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 53
Bio & Compensation  - Reuters
Israel F. Charo M.D., Ph.D. Senior Vice President - Research
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Ira Klein M.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 49
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 61
Bio & Compensation  - Reuters